Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Breakfast News - Zoltav Resources; LoopUP; Arix Biosciences and more...

Breakfast News - Zoltav Resources; LoopUP;  Arix Biosciences and more...

Small Cap Brunch

Set menu


Total number of AIM Companies (Incl Susp):


Total number of AIM Companies trading:


*as at close of business  9 May 2018

Standard List**  of Main Market:

Total number of Standard List Companies

(Incl Susp):


Total number of Standard List Companies trading:


*as at close of business  9 May 2018

NEX Growth Market:

Total number of NEX Growth Market Companies (Incl Susp):


Total number of NEX Growth Market Companies trading:


*as at close of business  9 May 2018                      

*A corporate client of Hybridan LLP

**  Standard Listing as defined by Hybridan LLP to be a business with strictly operational activity


Dish of the day

No Joiners Today

Off the menu  

No Leavers Today                        


Brunch Buffet

Zoltav Resources (LON:ZOL) 20.4p £28.96m

“The Russia-focused oil and gas exploration and production company, is pleased to announce the strengthening of its technical team with the appointments of former Bashneft and TNK-BP technical executives, Yuri Krasnevsky, as Director for Geology and Field Development, Andrei Zabolotnov, as Deputy Director for Field Development, and Vasily Fomichev, as Deputy Director for Geology. 

These senior appointments have been made in support of the Company's exploration programme to assess the resource potential of the Carbonian and Devonian structures in the Western Fields of the Bortovoy Licence, Saratov. An exploration programme to assess these structures began in 2017 with a substantial and ongoing 3D seismic acquisition programme, which the Company anticipates will allow for the positioning and drilling of the first Devonian exploration well on the North Mokrous area of the Mokrousovskoye block in due course.”


Arix Biosciences (LON:ARIX) 209p £281.6m

The “global healthcare and life science company supporting medical innovation, notes that its Group Business Iterum Therapeutics ("Iterum") a clinical-stage pharmaceutical company developing anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens, has filed an amended Form S-1 with the U.S. Securities and Exchange Commission in respect of its proposed initial public offering ("IPO") in the United States.

The amended Form S-1 filing states an expected pricing range for the proposed IPO of between $14.00 and $16.00 per share. This would represent a valuation of Arix's current holding in Iterum of between £7.0m and £8.1m (compared to cost to date of £9.0m).

The proposed maximum aggregate offering amount specified in the filing is US$85.3 million,.”


LoopUP (LON:LOOP) 474.9p £200.6m

“The premium remote meetings company, is pleased to announce that, subject to certain conditions, it has agreed to acquire the entire issued share capital of Warwick Holdco Limited, the holding company for the MeetingZone Group, a UK-headquartered conferencing services provider, from GMT Communications Partners on a debt-free and cash-free basis, for a total consideration of £61.4 million to be paid in cash (the "Acquisition").”

The Acquisition constitutes a reverse takeover under the AIM Rules . Proposed £50m placing at 400p.

The target has a consistent track record of profitability and grew to revenue of £22.5 million, gross profit of £15.0 million and Adjusted EBITDA of £5.0 million in the 12 months ended 31 December 2017 (unaudited pro forma).

FYDec18E rev £22m and PBT £3.17m.


Elecosoft (LON:ELCO) 73.9p £57.23m

“2018 has started well and Elecosoft's revenue for the four months ended 30 April 2018, based on unaudited management accounts, has increased by 7 per cent, compared with revenue for the same period last year at both actual and constant rates of exchange.

Profit Before Tax for the four months ended 30 April 2018, based on unaudited management accounts, was significantly higher than Profit before Tax for the same period last year and comfortably in line with market expectations, reflecting the benefit from higher revenue and continuing cost management.

John Ketteley, Executive Chairman said: "Elecosoft has continued to perform well reflecting both the strength and international spread of our core businesses. I am pleased to say that Elecosoft also continues to be strongly cash generative, and as at 30 April 2018 we had net cash of £2.4m, compared with net cash of £1.0m at 31 December 2017.”

 FYDec18E rev £22m and PBT £3.3m.


CloudCall (LON:CALL) 191p £46m

Launch of new Instant Messaging and SMS products, significantly enhancing its customers' ability to manage communications through multiple channels.

CloudCall's new messaging services will be offered as both free to use and paid-for premium versions, from which the Company expects to generate significant upsell opportunities and increased recurring revenues per user.

The new services are the first additional features to be launched using the Company's new unified architecture demonstrating the speed that new functionality can be built and delivered with this framework.  This software architecture also accelerates the speed at which CloudCall's unified communications functionality can be integrated with additional CRMs.

FY Dec18E rev £9.48m and £2.94m pre-tax loss.


Staffline (LOM:STAF) 979p £272.65m

 AGM Statement from the recruitment and Employability organisation.

"During the first four months of 2018 the Group has traded in line with Board and market expectations.

Despite a tight labour market, the Recruitment division has continued to perform strongly. Our size and scale allows us to meet growing customer demand and the three acquisitions so far this year have improved our coverage in specific geographic areas.”

“In PeoplePlus, the Group's Skills, Employability and Well-Being services division, the transition away from the Work Programme contracts remains on track. We are benefiting from our investment in the Apprenticeship Levy space and have made a good start to delivering Fair Start Scotland, which launched last month.” FYDec18E rev £1.1bn and PBT £36.47. PE c.9x. Yield c.3%.


Portmeiron Group (LON:PMP) 1116pp £121.1m

AGM Statement from the branded homewares specialist. 

"Total Group sales are up 15% for the four months ended 30 April 2018 relative to the same period last year, driven by strong growth in both ceramic and home fragrance product divisions. On a constant currency basis total Group sales are 20% ahead of last year. We are delighted with the start to the year, however due to the seasonal nature of our business and the importance of second half trading we continue to expect full year profit before tax to be in line with market expectations."

FYDec18E rev £87.1m and PBT £9.5m.


Kape Technologies (LON:KAPE) 121.56p £172.43m

AGM Statement. "I'm pleased to report that Kape continues to make excellent progress across all its key strategic growth drivers. With our rebranding now complete, our evolution into a consumer focused security software business is all but complete. Kape's stable of B2C software applications continues to grow in market share and our focus on both cross selling our applications, together with driving greater levels of recurring income, remains a key near term priority for management.

We continue to evaluate selective acquisitions to expand our product offering and broaden our reach in the growing market of security and privacy online. We have made a strong start to 2018 and look forward to updating the market on our continued progress." FYDec18E rev $50.8,m and PBT $5.69m


Medaphor Group (LON:MED) 8.5p £7.7m

AGM Statement from the intelligent ultrasound software and simulation company .

"The Group is trading in line with management's expectations, research and development work being undertaken by our Clinical Division is progressing well and Simulation Division sales in the UK and mainland Europe are showing good signs of recovery.  Initial orders placed in our key territories for our recently launched BodyWorks point of care and emergency medicine simulator are also encouraging."     

FYDec18E rev £5.43m and pre-tax loss £3.94m .


eServGlobal (LON:ESG) 9.25p £80.4m

AGM Statement from the digital transactions technology company . "2017 was a year in which we evidenced progress on both sides of our business, but ultimately we still need to deliver more proof that our strategy works today. We are focused on what is an improving picture for both eServGlobal and HomeSend. eServGlobal is now debt-free, with the core business benefitting from a much-reduced cost base, which is already showing signs of progress against a refreshed sales approach.

HomeSend, our JV with Mastercard and BICS, can support delivery of cross-border payments into over 100 countries. Growing numbers of banks have now been enabled to use HomeSend for their global payments solutions.” FYDec18E rev A$19m, and A$6m pre-tax loss.




This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use